| Date | Title | Description |
| 09.04.2026 | Landmarks Worldwide Light Up Blue for World Parkinson’s Day in Global 'Spark the Night' Movement | Team AbbVie Japan
This Saturday night, when you see blue, think Parkinson’s.
When the world lights up blue, it sends a powerful message — Parkinson’s deserves attention, urgency, and action. Every light helps raise awareness and push us clo... |
| 02.04.2026 | TippingPoint Biosciences: $4.5 Million Raised To Target Epigenetic Drivers In Pediatric Brain Cancer | TippingPoint Biosciences has raised $4.5 million in an oversubscribed seed funding round to advance a novel drug discovery platform focused on previously “undruggable” epigenetic targets. The financing was led by SOSV and LKS Fund, with par... |
| 01.04.2026 | TippingPoint Biosciences Raises $4.5M in Seed Funding | TippingPoint Biosciences, a San Francisco, CA-based biotechnology company, closed $4.5m in seed financing.
The round was led by SOSV and LKS Fund, with participation from Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innova... |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 24.03.2026 | World Parkinson Coalition® Launches Parkinson Ready™ Phoenix Program Ahead of 7th World Parkinson Congress | WPC teams up with the Muhammad Ali Parkinson Center, City of Phoenix and AbbVie to support the Parkinson’s community through its legacy training program
Visit Phoenix is honored to be part of the Parkinson’s Ready Program”
— Kylie Leslie, A... |
| 23.03.2026 | Allergan Aesthetics Helps Empower Consumers through Education as Medical Aesthetic Treatment Demand Grows | Bengaluru, Karnataka, India
Allergan Aesthetics, an AbbVie company, has announced the launch of A–Z of Medical Aesthetics, a consumer education initiative to improve understanding of aesthetics and help empower consumers in making informed ... |
| 23.03.2026 | Umlaut.bio extends pre-seed round to EUR 3 million |
Umlaut.bio is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules will be developed to inhibit key steps in tRNA modification synthesis, thereby preventi... |
| 19.03.2026 | Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director | Leadership addition expands agency's strategy capabilities amid continued growth
NEW YORK, March 19, 2026 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and healthcare, today announced t... |
| 18.03.2026 | FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi | Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde.
Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi.
J&J hasn’t announced how much Icotyde will cost. J&J sees annual sales ex... |
| 13.03.2026 | These stocks will benefit from AI and an aging population, Jefferies says. They also pay dividends | - |
| 12.03.2026 | The conditions are just right for this dividend-paying pharma stock as it mounts a comeback | - |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 28.02.2026 | Malaysia Elevates Workplace Excellence with Inaugural Best Workplaces List | Malaysia debuts its first globally recognized Best Workplaces list. Great Place To Work identified twenty leading organizations for 2026. This landmark initiative sets a new national benchmark. Employee feedback from over 45,000 workers dro... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 26.02.2026 | Great Place To Work® Announces First-Ever Best Workplaces™ in Malaysia 2026 | KUALA LUMPUR, Malaysia, Feb. 26, 2026 /PRNewswire/ -- Great Place To Work® ASEAN & ANZ today announced the inaugural Best Workplaces in Malaysia 2026, marking the first time the global authority on workplace culture has recognised outst... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 23.02.2026 | NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy | NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
Mon, Feb 23, 2026 10:51 CET Report this content
E... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 17.02.2026 | ALP AI receives CHF 40,000 from Venture Kick to translate organoid-AI platform into pilots | What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you?
Our first signal wasn’t a graph, it was a room. We pitched ALP AI to experienced pharma and healthcare experts ... |
| 11.02.2026 | Eli Lilly Secures Future with Orna Therapeutics Acquisition | Eli Lilly acquired Orna Therapeutics. The deal totals up to $2.4 billion. This secures groundbreaking circular RNA technology. Orna pioneers *in vivo* cell engineering. Their platform allows the body to generate therapies internally. This b... |
| 09.02.2026 | Фармкомпания Eli Lilly покупает американскую биотех-компанию Orna Therapeutics за $2,4 млрд | Американская фармацевтическая компания Eli Lilly (LLY.N) согласилась купить биотехнологическую компанию Orna Therapeutics за $2,4 млрд наличными, получив доступ к технологии, которая позволяет использовать собственные клетки пациентов для с... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 25.01.2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| 21.01.2026 | GSK приобретает компанию RAPT Therapeutics за $2,2 млрд | Сделка, одна из первых крупных в 2026 году, предусматривает выплату $58,00 за акцию при закрытии сделки, что оценивает общий капитал компании примерно в $2,2 млрд. Это существенно выше стоимости акций RAPT на закрытии 16 января, которая сос... |
| 19.01.2026 | Chinese Innovative Drugs' Global Rise Is Hot Topic at JP Morgan Healthcare Conference | (Yicai) Jan. 19 -- Chinese innovative drugs were an unavoidable topic among participants at the 44th annual JP Morgan Healthcare Conference due to their growing importance in the global pharmaceutical industry, with discussion focusing on i... |
| 14.01.2026 | Landmark AbbVie-Trump Deal Reshapes Drug Access, Ignites U.S. Pharma Investment | A monumental three-year agreement reshapes pharmaceutical access. The Trump administration and AbbVie forged a new path. AbbVie will dramatically reduce drug prices within Medicaid. It will also expand direct-to-patient offerings through th... |
| 13.01.2026 | AbbVie And Trump Administration Strike $100 Billion Deal Tied To Medicaid Prices, Direct-To-Patient Drug Access, And U.S. Investment Plan | AbbVie announced it has reached a voluntary, three-year agreement with the Trump administration aimed at expanding access to medicines and lowering costs for Americans, while the company commits to a decade-long investment push in U.S. rese... |
| 13.01.2026 | AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans | AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx
AbbVie will commit $100 billion in U.S. research and development (R&D) and capit... |
| 12.01.2026 | В медицинском секторе ожидают новый виток крупных M&A-сделок в 2026 году | Участники рынка слияний и поглощений в сфере здравоохранения на этой неделе съезжаются в Сан-Франциско накануне 43-й ежегодной конференции JPMorgan Healthcare Conference, рассчитывая на новую волну мега-слияний в 2026 году, которая по масшт... |
| 12.01.2026 | Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and P... | TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil&q... |
| 10.01.2026 | UPenn, BioNTech, And Osage University Partners Launch $50 Million Seed Fund To Back Penn Life Science Startups | The University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a dedicated venture fund focused on early-stage life scienc... |
| 01.01.2026 | Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen | CHENGDU, China, Jan. 1, 2026 /PRNewswire/ -- As the Year of the Horse begins, bringing new momentum and promise, Living Phoenix—a pioneer in next-generation biomaterials—wishes all friends, partners, and users a joyful New Year.
May you sta... |
| 21.12.2025 | Трамп договорился с фармакомпаниями о снижении цен на лекарства для хронических болезней | - |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 15.12.2025 | AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List | SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Mala... |
| 15.12.2025 | uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials | On behalf of the Critical Path Institute (C-Path) Florence Mowlem PhD, led this much-needed project, providing 10 best practices for EDeD design and implementation to support clinical trial data capture, along with co-authors from Top 10 ph... |
| 09.12.2025 | Amaris B. Clinic 2026 Forecast: Corrective & Restorative Procedures Demand Increases to Address Post-GLP-1 Weight Loss Aesthetic Concerns | The clinic identifies a significant shift from aesthetic enhancement to comprehensive restoration, driven by the physical consequences of rapid weight reduction.
SINGAPORE – Media OutReach Newswire – 9 December 2025 – The widespread use of ... |
| 05.12.2025 | AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer | - Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3]
SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored s... |
| 10.11.2025 | [CIIE] Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply | (Yicai) Nov. 10 -- Simcere Pharmaceutical Group showed its redefined cross-border collaboration model at the eighth China International Import Expo, with the Chinese company to soon start manufacturing in China an insomnia drug it licensed ... |
| 06.11.2025 | Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study | Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study.
The highest dose of the weekly injection, called eloralintide, helped patients with ... |
| 05.11.2025 | FDA warns websites selling unapproved Botox for cosmetic purposes | By MATTHEW PERRONE
U.S. health regulators on Wednesday sent warning letters to 18 websites selling counterfeit or unapproved versions of Botox and similar injectable drugs commonly used to smooth wrinkles. Related Articles
Officials scour c... |
| 05.11.2025 | Federal judge won’t block Colorado prescription drug discount law | A federal judge declined to block a Colorado law that requires drugmakers to offer discounted medications to more pharmacies, but a lawsuit challenging the legislation can still proceed.
Drugmaker AbbVie sued the state in June because of Se... |
| 31.10.2025 | Amazon carries Wall Street to the finish of another winning week and month | By STAN CHOE, AP Business Writer
NEW YORK (AP) — Amazon led the U.S. stock market on Friday to the finish of another winning week and month.
The S&P 500 rose 0.3% and pulled closer to its all-time high set on Tuesday. It closed out a th... |
| 19.10.2025 | Osteoporosis in men? Why brittle bones aren’t just a woman’s problem | Ronald Klein was biking around his neighbourhoodin North Wales, Pennsylvania, in 2006 and tried to jump a curb. “But I was going too slow – I didn’t have enough momentum,” he recalled.
As the bike toppled, he thrust out his left arm to brea... |
| 06.10.2025 | AbbVie понизила прогноз прибыли из-за крупных расходов на разработки | - |
| 04.10.2025 | AbbVie trims annual profit forecast after expected $2.7 billion R&D hit | AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
By ReutersOctober 3, 202510:13 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Test tubes are seen in front of a displ... |
| 03.10.2025 | Drug Price Revolution: Pfizer Deal Ignites Market, Reshapes Industry | A landmark Pfizer deal with the Trump administration significantly alters US drug pricing. The agreement promises lower Medicaid costs and 'most-favored nation' launch pricing for new pharmaceuticals, ensuring Americans pay no more than oth... |
| 02.10.2025 | 73 Thailand Companies Tackle Talent Crisis With Innovation, Flexibility, and Tech | BANGKOK, Oct. 1, 2025 /PRNewswire/ -- The HR Asia Best Companies to Work for in Asia organized by Business Media International, returns to Thailand — shining a spotlight on 73 organisations that are not only surviving these challenges but t... |
| 01.10.2025 | US Pfizer deal powers health stocks as drugmakers court Trump | US Pfizer deal powers health stocks as drugmakers court Trump
By Alun John, Danilo Masoni, Dimitri Rhodes and Maggie FickOctober 1, 20258:01 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Summa... |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 30.09.2025 | Глобальный рынок M&A в 2025 году превысил $3 трлн на фоне рекордного числа крупных сделок | Летом было объявлено 14 транзакций стоимостью более $10 млрд, что стало самым активным периодом по сделкам за последние годы. Среди крупнейших операций — поглощение Union Pacific компанией Norfolk Southern за $85 млрд, слияние Anglo America... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 29.09.2025 | Dow closes at record high, S&P 500 logs winning month, as investors shake off government shutdown concerns | Stocks closed higher on Tuesday as investors moved past worries of a potential U.S. government shutdown and logged an unusually strong September.
The S&P 500 closed up 0.41% at 6,688.46, while the Nasdaq Composite climbed 0.31% to finis... |
| 29.09.2025 | Датская Genmab покупает нидерландскую фармкомпанию Merus за $8 млрд | Genmab выкупит акции Merus по цене $97 за штуку наличными, говорится в совместном заявлении компаний в понедельник. Это примерно на 41% выше цены закрытия акций Merus, котирующихся в США, по состоянию на 26 сентября. Ранее Bloomberg News со... |
| 26.09.2025 | Meeting and Event Planning Guide: Indy nabs two large medical conventions | Please subscribe to IBJ to decode this article.
c elhalrr unr rmegcebhro eIeoxheosas hattTar ltemn.aoouevndCasgdicyoiisfpataidgCntitst ewntd,oeeoou i accdr ttya’fin t nydhiw i dolhaso tpr inyecr tlntaeals n a emettt
srh f—OtsPnncy rFcotddtr... |
| 12.09.2025 | "Celebrate!" Great Place To Work™ Greater China Celebrates the Best Workplaces™ in Taiwan 2025 | TAIPEI, Sept. 12, 2025 /PRNewswire/ -- On September 11th, Great Place To Work™ Greater China held the Best Workplaces™ in Taiwan 2025 Awards Ceremony at the W Hotel Taipei.
This event aims to set apart the awarded companies from others by p... |
| 12.09.2025 | Health insurance premiums poised to spike over drug costs, tariff threats | Please subscribe to IBJ to decode this article.
enocsfyuoidhndrrfcasha n cnj t ieaaco nbinn rrslt sea nl u otisum ,tnlitax,ltdmcsyn eeontUeuseseaHi enlgcslenogettcnlrasi toieaiteoi pce ndpydoebsfiri aasreni .vdtoreal Aueieaelpbenutr a gSa t... |
| 12.09.2025 | AbbVie сохранит эксклюзив на препарат от аутоиммунных заболеваний до 2037 года | - |
| 11.09.2025 | AbbVie shares hit record high as key immunology drug set for exclusivity until 2037 | AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
By Christy SanthoshSeptember 11, 20254:27 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A sign stands outsid... |
| 09.09.2025 | Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie | - |
| 01.09.2025 | AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work | SINGAPORE, Sept. 1, 2025 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, has selected AbbVie for the 2025 Best Workplaces in Asia™ List, ranking the company No. 7 up from No. 8 last year.
This year's list wa... |
| 25.08.2025 | AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B | What You Should Know:
– AbbVie and Gilgamesh Pharmaceuticals Inc. have announced a definitive agreement for AbbVie to acquire Gilgamesh’s lead investigational candidate, bretisilocin, which is in clinical development for the treatment of pa... |
| 18.08.2025 | Glenmark expects ISB 2001 deal with AbbVie to close in September | - |
| 07.08.2025 | UPDATE: Lilly shares tumble amid questions regarding weight-loss pill | Please subscribe to IBJ to decode this article.
artep gdsooe rdm fy nesenorygiast g1tsa4tpeanh natda sadloeot.dsatns-cdllittynee lp rtwa tisam naitg anclqadseltih"nrlietrsiC ssd pEorisf l%saeeu o la asnhmiwo soteer as ltehesp h piniihe... |
| 06.08.2025 | Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Moon Rabbit
Independent agency forges key industry partnerships, hires 28 new employees to fuel expansion
NEW YORK, Aug. 6, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and health... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 01.08.2025 | European drugmakers fall after Trump raises stakes over US drug price cuts | European drugmakers fall after Trump raises stakes over US drug price cuts
By Ankur BanerjeeAugust 1, 20258:30 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Novo Nordisk flags flutter outside ... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 25.07.2025 | AbbVie’s First in Class Therapy ELAHERE[®] ▼ (mirvetuximab soravtansine) Licensed by the MHRA for the Treatment of Eligible Adult Patients with Platinum-Resistant Ovarian Cancer | AbbVie’s First in Class Therapy ELAHERE[®] ▼ (mirvetuximab soravtansine) Licensed by the MHRA for the Treatment of Eligible Adult Patients with Platinum-Resistant Ovarian Cancer
Fri, Jul 25, 2025 12:29 CET Report this content
For UK consume... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong.
In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 18.07.2025 | The Invisible Tsunami: Deep Science Ventures and Grantham Foundation sound alarm on toxicity crisis | This week sees the launch of a report from Deep Science Ventures and the Grantham Foundation for the Protection of the Environment, which reveals that the extent of toxic chemical exposure in air, food, and water is higher than previously r... |
| 16.07.2025 | AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact | - 880 AbbVie employees across 7 markets volunteered over 3,000 hours to support vulnerable groups.
- Over 650 individuals benefited from 24 volunteer initiatives, delivered in partnership with 17 community organisations across the region.
S... |
| 11.07.2025 | "Celebrate!" Great Place To Work™ Greater China Celebrates the Best Workplaces™ in Hong Kong 2025 | HONG KONG, July 11, 2025 /PRNewswire/ -- On July 10th, Great Place To Work™ Greater China held the Best Workplaces™ in Hong Kong 2025 Awards Ceremony at Maggie Choo's.
The Best Workplaces™ in Hong Kong 2025 celebration at Maggie Choo's in H... |
| 10.07.2025 | Glenmark subsidiary IGI inks $700-m deal on cancer drug candidate with multinational AbbVie | - |
| 08.07.2025 | Wall Street ends mixed amid Trump’s new tariff deadlines | “I think today you’re basically seeing a market that doesn’t quite believe the worst of this is going to come to bear and is just kind of waiting for any sort of clarity because we seem back in that in that kind of phase where things change... |
| 08.07.2025 | Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’ | President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”
But he suggested that those levies would not go into effect immediately, saying he will “give people about a year, year an... |
| 04.07.2025 | Everest Medicines targets global expansion with proprietary, AI-driven mRNA platform | After years of building a robust commercial base through in-licensing, Hong Kong-listed biopharmaceutical firm Everest Medicines is entering a new phase of growth: one defined by a “dual-engine” strategy that blends in-house innovation with... |
| 02.07.2025 | AbbVie купит Capstan Therapeutics для развития CAR-T терапии | - |
| 01.07.2025 | The Gene Revolution: Laverock Therapeutics and AbbVie’s Bold Moves in Biotech | In the ever-evolving landscape of biotechnology, two stories stand out like beacons of innovation. Laverock Therapeutics, a London-based startup, has raised over €23.3 million to advance its gene control technology. Meanwhile, AbbVie, a gia... |
| 30.06.2025 | Американский AbbVie покупает разработчика клеточной терапии Capstan за $2,1 млрд | Американский производитель лекарств AbbVie потратил более $20 млрд на приобретения с 2023 года, когда его флагманский препарат для лечения ревматоидного артрита Хумира утратил патентную защиту.
Capstan разрабатывает CAR-T-терапию, которая и... |
| 19.06.2025 | Big Pharma Under Fire: A Taxing Debate in the Senate | The Senate floor is heating up. Two Democratic lawmakers, Sen. Elizabeth Warren and Rep. Jan Schakowsky, are shining a spotlight on the pharmaceutical giants. Pfizer, Johnson & Johnson, Merck, AbbVie, and Amgen are in the crosshairs. Th... |
| 19.06.2025 | Revolutionizing Cancer Treatment: Simcere Zaiming's Breakthrough in Multiple Myeloma Therapy | In the ever-evolving landscape of oncology, breakthroughs often emerge from the shadows of research labs. Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, is stepping into the spotlight with its innovative therapy for relapsed... |
| 19.06.2025 | Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma | SHANGHAI, June 19, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-10... |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 17.06.2025 | Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump’s plan | Two Democratic lawmakers on Tuesday pressed five of the nation’s largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the GOP reconciliation bill.
Sen. Elizabeth ... |
| 13.06.2025 | Indianapolis-based startup leans on connections to treat brain diseases | Please subscribe to IBJ to decode this article.
so" co7tniifn:wct=l l5m=/nne4bBc_omtI"/ioaedel"-_oii=ii0-edidC5a2ru["00-mca5ae=fud othmtwi1ga"e"3r"daletl0ca]nsene d vy.sdstiheip =loto jee6teo mpts m3t [c6i... |
| 10.06.2025 | Drug pricing reform talks with US government lack clarity, industry executives say | Drug pricing reform talks with US government lack clarity, industry executives say
By Bhanvi Satija and Christy SanthoshJune 10, 20258:34 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 o... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 04.06.2025 | Health-care stocks are due for a turnaround after a historically bad month, according to the charts | - |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 14.05.2025 |
Jim Cramer suggests why it’s hard to own traditional ‘safety’ stocks here | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer reviewed why certain stocks that usually considered safe bets — like pharmaceuticals or consumer packaged goods — weathered losses on Wednesday.
He pointed to rising bond yields and uncer... |
